The impact on the multidisciplinary team of molecular profiling for personalized therapy in non-small cell lung cancer

Lung Cancer

Volumn 79, Issue 2, 2013, Pages 101-103

  Blackhall, Fiona ^a   Thatcher, Nick ^a   Booton, Richard ^b   Kerr, Keith ^c  

^a CHRISTIE HOSPITAL   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

^c ABERDEEN ROYAL INFIRMARY   (United Kingdom)

Author keywords

ALK; Crizotinib; EGFR; FISH; Multidisciplinary; Non small cell lung cancer; Personalized therapy

Indexed keywords

CRIZOTINIB; GEFITINIB; VASCULOTROPIN RECEPTOR;

CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; GENE REARRANGEMENT; GENETIC SCREENING; HEALTH CARE PERSONNEL; HUMAN; LUNG NON SMALL CELL CANCER; MULTIDISCIPLINARY TEAM; PERSONALIZED MEDICINE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW;

ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; GENETIC TESTING; HUMANS; INDIVIDUALIZED MEDICINE; LUNG NEOPLASMS; PATIENT CARE TEAM; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84872168494     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2012.10.016     Document Type: Review

References (5)

1. Mok T.S., Wu Y.L., Thongprasert S., Yang C.H., Chu D.T., Saijo N., et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009, 361:947-957.
2. Camidge D.R., Bang Y., Kwak E.L., Shaw A.T., Lafrate A.J., Maki R.G., et al. Progression-free survival (PFS) from a phase I study of crizotinib (PF-02341066) in patients with ALK-positive non-small cell lung cancer (NSCLC). J Clin Oncol 2011, 29(Suppl.). [Abstract 2501].
3. Paik J.H., Choe G., Kim H., Choe J.Y., Lee H.J., Lee C.T., et al. Screening of anaplastic lymphoma kinase rearrangement by immunohistochemistry in non-small cell lung cancer: correlation with fluorescence in situ hybridization. J Thorac Oncol 2011, 6:466-472.
4. Cagle P.T., Allen T.C., Dacic S., Beasley M.B., Borczuk A.C., Chirieac L.R., et al. Revolution in lung cancer: new challenges for the surgical pathologist. Arch Pathol Lab Med 2011, 135:110-116.
5. Kerr K.M. Personalized medicine for lung cancer: new challenges for pathology. Histopathology 2012, 60:531-546.